BAT – 101
Depression is a worldwide problem with more than 300 million people affected. With the dualism theory of the mind and body being related, as a result, more than a million people suffer from this disorders across the globe.
There are many antidepressants available which reduces the intensity and period of depression but come with a variety of side effects like memory loss, headaches, nausea, dizziness, fatigue etc.
BioAgile Therapeutics has ventured into this field of drug discovery and has discovered BAT-101, a class of antidepressant with limited side effects. The patent has been filed with the number E-2/2189/2018-CHE and it is currently in the in-vitro phase.
BAT – 102
Psoriasis is an immune-mediated disease that causes raised, red, scaly patches to appear on the skin.
It typically affects the outside of the elbows, knees or scalp, though it can appear on any location. Psoriasis is associated with other serious health conditions, such as diabetes, heart disease and depression.
BioAgile has filed patent for Psoriasis drug with patent number E-2/2840/2018-CHE.
The molecule is an antipsoriatic drug has pharmacodynamics active ingredient that prevent/treat psoriasis.
The molecule can be used for all skin inflammations and is safe with minimum side effects and the molecule is currently in invitro phase.